OR WAIT null SECS
May 27, 2021
RGX-314 eyed by investigators as a therapeutic option for exudative AMD.
May 25, 2021
Preexisting neutralizing antibodies associated with the inflammatory changes.
May 20, 2021
Study results show that aflibercept-treated eyes are protected.
January 28, 2021
Annual Bascom Palmer Eye Institute program will spotlight latest advances in neovascular and exudative ocular disease over 2-day event, February 12-13.
Three sessions cover the range from clinical updates for imaging to emerging therapies for non-exudative AMD.
The program features an update on faricimab, plus diabetes, choroiditis, retinitis pigmentosa, and late-breaking reports.
